Zions Bancorporation N.A. Sells 3,848 Shares of Sanofi (NASDAQ:SNY)

Zions Bancorporation N.A. trimmed its position in Sanofi (NASDAQ:SNY) by 2.4% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 154,360 shares of the company’s stock after selling 3,848 shares during the period. Sanofi comprises approximately 0.6% of Zions Bancorporation N.A.’s holdings, making the stock its 19th largest holding. Zions Bancorporation N.A.’s holdings in Sanofi were worth $8,896,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of SNY. Allspring Global Investments Holdings LLC boosted its position in Sanofi by 773.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock valued at $275,000 after buying an additional 5,004 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Sanofi by 3.0% in the 1st quarter. SG Americas Securities LLC now owns 15,690 shares of the company’s stock worth $763,000 after purchasing an additional 456 shares during the last quarter. US Bancorp DE boosted its position in shares of Sanofi by 3.2% in the 1st quarter. US Bancorp DE now owns 90,118 shares of the company’s stock worth $4,380,000 after purchasing an additional 2,780 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Sanofi by 7.1% in the 1st quarter. ProShare Advisors LLC now owns 19,197 shares of the company’s stock worth $933,000 after purchasing an additional 1,268 shares during the last quarter. Finally, Orion Portfolio Solutions LLC boosted its position in shares of Sanofi by 8.4% in the 1st quarter. Orion Portfolio Solutions LLC now owns 56,077 shares of the company’s stock worth $2,725,000 after purchasing an additional 4,357 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on SNY. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Argus raised their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

Shares of Sanofi stock opened at $49.51 on Thursday. The company has a market capitalization of $125.65 billion, a PE ratio of 25.26, a PEG ratio of 1.28 and a beta of 0.61. Sanofi has a 12 month low of $45.13 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $55.05 and its 200 day simple moving average is $52.23.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.55 EPS. On average, research analysts predict that Sanofi will post 4.27 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.